##ANALYSISTYPE=SOMATIC_PAIR
##PIPELINE=megSAP 0.2-150-gb0708b9
##SAMPLE=<ID=DX000000_01,Gender=male,ExternalSampleName=DNA-200770 A1,IsTumor=yes,IsFFPE=yes,DiseaseGroup=n/a,DiseaseStatus=n/a>
##SAMPLE=<ID=DX000000_01,Gender=male,ExternalSampleName=DNA-200448 A1,IsTumor=no,IsFFPE=no,DiseaseGroup=n/a,DiseaseStatus=n/a>
##CGI_CANCER_TYPE=REC
##DESCRIPTION=filter=Annotations for filtering and ranking variants.
##DESCRIPTION=quality=Quality parameters - variant quality (QUAL), depth (DP), allele frequency (AF), mean mapping quality of alternate allele (MQM).
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, ENST number, type, impact, exon/intron number, HGVS.c, HGVS.p, Pfam domain).
##DESCRIPTION=coding_and_splicing_refseq=Coding and splicing details based on RefSeq (Gene, RefSeq id, type, impact, exon/intron number, HGVS.c, HGVS.p, Pfam domain).
##DESCRIPTION=regulatory=Regulatory consequence details.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=1000g=Allele frequency in 1000 genomes project.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD project.
##DESCRIPTION=gnomAD_hom_hemi=Homoyzgous counts and hemizygous counts of gnomAD project (genome data).
##DESCRIPTION=gnomAD_sub=Sub-population allele frequenciens (AFR,AMR,EAS,NFE,SAS) in gnomAD project.
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=Sift=Sift effect prediction and score for each transcript: D=damaging, T=tolerated.
##DESCRIPTION=PolyPhen=PolyPhen (humVar) effect prediction and score for each transcript: D=probably damaging, P=possibly damaging, B=benign.
##DESCRIPTION=fathmm-MKL=fathmm-MKL score (for coding/non-coding regions). Deleterious threshold > 0.5.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 10-20.
##DESCRIPTION=REVEL=REVEL pathogenicity prediction score. Deleterious threshold > 0.5.
##DESCRIPTION=MaxEntScan=MaxEntScan splicing prediction (reference bases score/alternate bases score).
##DESCRIPTION=GeneSplicer=GeneSplicer splicing prediction (state/type/coordinates/confidence/score).
##DESCRIPTION=dbscSNV=dbscSNV splicing prediction (ADA/RF score).
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=NGSD_som_c=Somatic variant count in the NGSD.
##DESCRIPTION=NGSD_som_p=Project names of project containing this somatic variant in the NGSD.
##DESCRIPTION=NGSD_hom=Homozygous variant count in NGSD.
##DESCRIPTION=NGSD_het=Heterozygous variant count in NGSD.
##DESCRIPTION=NGSD_group=Homozygous / heterozygous variant count in NGSD with the same disease group (Neoplasms).
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validation=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Variant comments from the NGSD.
##DESCRIPTION=gene_info=Gene information from NGSD (inheritance mode, gnomAD o/e scores).
##DESCRIPTION=tumor_af=Mutant allele frequency in tumor (Sample DX000000_01).
##DESCRIPTION=tumor_dp=Tumor Depth (Sample DX000000_01).
##DESCRIPTION=normal_af=Mutant allele frequency in normal (Sample DX000000_01).
##DESCRIPTION=normal_dp=Normal depth (Sample DX000000_01).
##DESCRIPTION=somatic_classification_comment=Somatic classificaiton comment from the NGSD.
##DESCRIPTION=somatic_classification=Somatic classification from the NGSD.
##DESCRIPTION=CGI_id=Identifier for CGI statements
##DESCRIPTION=CGI_driver_statement=CancerGenomeInterpreter.org oncogenic classification
##DESCRIPTION=CGI_gene_role=CancerGenomeInterpreter.org gene role. LoF: Loss of Function, Act: Activating
##DESCRIPTION=CGI_transcript=CancerGenomeInterpreter.org CGI Ensembl transcript ID
##DESCRIPTION=CGI_gene=Gene symbol returned by CancerGenomeInterpreter.org
##DESCRIPTION=CGI_consequence=Consequence of the mutation assessed by CancerGenomeInterpreter.org
##DESCRIPTION=ncg_oncogene=1:gene is oncogene according NCG6.0, 0:No oncogene according NCG6.0, na: no information available about gene in NCG6.0. Order is the same as in column gene.
##DESCRIPTION=ncg_tsg=1:gene is TSG according NCG6.0, 0:No TSG according NCG6.0, na: no information available about gene in NCG6.0. Order is the same as in column gene.
##FILTER=LowDepth=Tumor or normal sample read depth at this locus is below 2
##FILTER=LowEVS=Somatic Empirical Variant Score (SomaticEVS) is below threshold
##FILTER=all-unknown=Allele unknown
##FILTER=depth-nor=Sequencing depth in normal is too low (< 20)
##FILTER=depth-tum=Sequencing depth in tumor is too low (< 20)
##FILTER=freq-nor=Allele frequency in normal > 0.17 * allele frequency in tumor
##FILTER=freq-tum=Allele frequency in tumor < 0.05
##FILTER=lt-3-reads=Less than 3 supporting tumor reads
##FILTER=off-target=Variant marked as 'off-target'.
##FILTER=special-chromosome=Special chromosome
#chr	start	end	ref	obs	tumor_af	tumor_dp	normal_af	normal_dp	filter	quality	gene	variant_type	coding_and_splicing	coding_and_splicing_refseq	regulatory	OMIM	ClinVar	HGMD	RepeatMasker	dbSNP	1000g	gnomAD	gnomAD_hom_hemi	gnomAD_sub	phyloP	Sift	PolyPhen	fathmm-MKL	CADD	REVEL	MaxEntScan	GeneSplicer	dbscSNV	COSMIC	NGSD_som_c	NGSD_som_p	NGSD_hom	NGSD_het	NGSD_group	classification	classification_comment	somatic_classification	somatic_classification_comment	validation	comment	gene_info	CGI_id	CGI_driver_statement	CGI_gene_role	CGI_transcript	CGI_gene	CGI_consequence	ncg_oncogene	ncg_tsg
chr1	96912431	96912431	C	A	0.1931	202	0.0000	126	off-target	QUAL=144	EEF1A1P11	upstream_gene	EEF1A1P11:ENST00000415278:upstream_gene_variant:MODIFIER::::	::intergenic_variant:MODIFIER::::	regulatory_region_variant:promoter					rs952373168					0.7580			0.18,0.89	9.19						0		0	0	0 / 0							EEF1A1P11 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)							na	na
chr1	120110725	120110725	A	G	0.1111	63	0.0000	68	off-target	QUAL=78	HSD3BP4	intron&non_coding_transcript	HSD3BP4:ENST00000511509:intron_variant&non_coding_transcript_variant:MODIFIER:intron2/2:n.308+49A>G::	HSD3BP4:NR_033781.1:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.4223A>G::						rs12727809	0.5032	0.0043	2,.		-2.7030			0.00,0.03	0.17						10	Leuk,Roecken_CheckpointInhibitor,SomaticAndTreatment	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							HSD3BP4 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)							na	na
chr1	120495937	120495937	A	-	0.7500	6	0.0000	8	depth-tum;depth-nor;off-target	QUAL=4	NOTCH2	intron	NOTCH2:ENST00000256646:intron_variant:MODIFIER:intron14/33:c.2365+229del::	NOTCH2:NM_001200001.1:intron_variant:MODIFIER:intron14/21:c.2365+229del::,NOTCH2:NM_024408.3:intron_variant:MODIFIER:intron14/33:c.2365+229del::,NOTCH2:XM_005270901.1:intron_variant:MODIFIER:intron14/33:c.2248+229del::,NOTCH2:XM_005270902.1:intron_variant:MODIFIER:intron14/33:c.2248+229del::		600275 [GENE=NOTCH2 PHENOS=Hajdu-Cheney syndrome,102500,Autosomal dominant/Alagille syndrome 2,610205,Autosomal dominant];			AluSp (SINE/Alu)			0.0106	1,.		0.7230				0.89						5	SomaticAndTreatment	0	4	0 / 0							NOTCH2 (inh=AD oe_syn=1.02 oe_mis=0.73 oe_lof=0.06)	chr1_120495936_CA_C	not protein-affecting	ambiguous	ENST00000256646	NOTCH2	IntronicDeletion	0	0
chr1	155206368	155206368	G	A	0.1816	381	0.0000	207	off-target	QUAL=197	GBA	intron	GBA:ENST00000327247:intron_variant:MODIFIER:intron8/11:c.1000-108C>T::,GBA:ENST00000368373:intron_variant:MODIFIER:intron7/10:c.1000-108C>T::,GBA:ENST00000427500:intron_variant:MODIFIER:intron6/9:c.853-108C>T::,GBA:ENST00000428024:intron_variant:MODIFIER:intron6/9:c.739-108C>T::,GBA:ENST00000536770:intron_variant:MODIFIER:intron5/8:c.661-108C>T::	GBA:NM_000157.3:intron_variant:MODIFIER:intron7/10:c.1000-108C>T::,GBA:NM_001005741.2:intron_variant:MODIFIER:intron8/11:c.1000-108C>T::,GBA:NM_001005742.2:intron_variant:MODIFIER:intron8/11:c.1000-108C>T::,GBA:NM_001171811.1:intron_variant:MODIFIER:intron6/9:c.739-108C>T::,GBA:NM_001171812.1:intron_variant:MODIFIER:intron6/9:c.853-108C>T::,GBA:XM_005245087.1:intron_variant:MODIFIER:intron5/8:c.661-108C>T::	regulatory_region_variant:promoter_flanking_region	606463 [GENE=GBA PHENOS=Gaucher disease,type III,231000,Autosomal recessive/Parkinson disease,late-onset,susceptibility to,168600,Autosomal dominant,Multifactorial/Gaucher disease,type IIIC,231005,Autosomal recessive/Gaucher disease,type I,230800,Autosomal recessive/Gaucher disease,perinatal lethal,608013,Autosomal recessive/Gaucher disease,type II,230900,Autosomal recessive/Lewy body dementia,susceptibility to,127750,Autosomal dominant];									0.5680			0.02,0.14	3.71						0		0	0	0 / 0							MTX1P1 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a), GBA (inh=AR oe_syn=1.05 oe_mis=0.81 oe_lof=0.51)	chr1_155206368_G_A	not protein-affecting	.	ENST00000327247	GBA	IntronicSNV	na	na
chr1	205454275	205454277	AGA	-	0.8571	9	0.0000	3	depth-tum;depth-nor;off-target	QUAL=1		intergenic	::intergenic_variant:MODIFIER::::	::intergenic_variant:MODIFIER::::	regulatory_region_variant:promoter_flanking_region				GA-rich (Low_complexity)	rs138104191	0.2139	0.1886	565,.		0.4610				1.07						4	Novartis,SomaticAndTreatment	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)														na	na
chr2	951717	951722	GCCCCT	-	0.8889	11	0.0000	3	depth-tum;depth-nor;off-target	QUAL=1	SNTG2	intron	SNTG2:ENST00000308624:intron_variant:MODIFIER:intron1/16:c.72+4987_72+4992del::,SNTG2:ENST00000407292:intron_variant:MODIFIER:intron1/10:c.72+4987_72+4992del::	SNTG2:NM_018968.3:intron_variant:MODIFIER:intron1/16:c.72+4987_72+4992del::,SNTG2:XM_005264695.1:intron_variant:MODIFIER:intron1/10:c.72+4987_72+4992del::					(CTGCCC)n (Simple_repeat)	rs550449157	0.1170	0.1914	538,.		0.4110				0.94						2	Novartis,SomaticAndTreatment	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							SNTG2 (inh=n/a oe_syn=0.98 oe_mis=1.03 oe_lof=0.80)	chr2_951716_GGCCCCT_G	not protein-affecting	.	ENST00000308624	SNTG2	IntronicDeletion	na	na
chr2	198262521	198262521	A	-	0.3571	20	0.0000	6	depth-nor;off-target	QUAL=1	SF3B1	intron	SF3B1:ENST00000335508:intron_variant:MODIFIER:intron22/24:c.3266+188del::	SF3B1:NM_012433.2:intron_variant:MODIFIER:intron22/24:c.3266+188del::,SF3B1:NM_012433.3:intron_variant:MODIFIER:intron22/24:c.3266+188del::,SF3B1:XM_005246428.1:intron_variant:MODIFIER:intron23/25:c.2828+188del::,SF3B1:XR_241300.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron23/24:n.3428+188del::		605590 [GENE=SF3B1 PHENOS=Myelodysplastic syndrome,somatic,614286];			AluSz (SINE/Alu)	rs1419961106		0.0201	0,.		0.5760				0.24						4	SomaticAndTreatment	0	1	0 / 0							SF3B1 (inh=n/a oe_syn=0.98 oe_mis=0.19 oe_lof=0.01)	chr2_198262520_CA_C	not protein-affecting	Act	ENST00000335508	SF3B1	IntronicDeletion	1	0
chr3	142215121	142215121	T	A	0.1429	42	0.0000	16	depth-nor;off-target	QUAL=63	ATR	intron	ATR:ENST00000350721:intron_variant:MODIFIER:intron34/46:c.5898+82A>T::,ATR:ENST00000383101:intron_variant:MODIFIER:intron33/45:c.5706+82A>T::	ATR:NM_001184.3:intron_variant:MODIFIER:intron34/46:c.5898+82A>T::,ATR:XR_241498.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron34/46:n.5987+82A>T::		601215 [GENE=ATR PHENOS=Seckel syndrome 1,210600,Autosomal recessive/Cutaneous telangiectasia and cancer syndrome,familial,614564,Autosomal dominant];			(TA)n (Simple_repeat)	rs73864545		0.2293	550,.		0.9090			0.00,0.07	4.19						1	SomaticAndTreatment	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							ATR (inh=AR+AD oe_syn=0.95 oe_mis=0.67 oe_lof=0.31)	chr3_142215121_T_A	not protein-affecting	LoF	ENST00000350721	ATR	IntronicSNV	0	1
chr3	142215122	142215122	A	T	0.1463	41	0.0000	16	depth-nor;off-target	QUAL=63	ATR	intron	ATR:ENST00000350721:intron_variant:MODIFIER:intron34/46:c.5898+81T>A::,ATR:ENST00000383101:intron_variant:MODIFIER:intron33/45:c.5706+81T>A::	ATR:NM_001184.3:intron_variant:MODIFIER:intron34/46:c.5898+81T>A::,ATR:XR_241498.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron34/46:n.5987+81T>A::		601215 [GENE=ATR PHENOS=Seckel syndrome 1,210600,Autosomal recessive/Cutaneous telangiectasia and cancer syndrome,familial,614564,Autosomal dominant];			(TA)n (Simple_repeat)	rs201323437	0.5309	0.5415	527,.		-0.3720			0.00,0.15	1.18						1	SomaticAndTreatment	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							ATR (inh=AR+AD oe_syn=0.95 oe_mis=0.67 oe_lof=0.31)	chr3_142215122_A_T	not protein-affecting	LoF	ENST00000350721	ATR	IntronicSNV	0	1
chr3	155027585	155027585	G	A	0.1308	759	0.0000	507	off-target	QUAL=265	PABPC1P10	non_coding_transcript_exon	PABPC1P10:ENST00000464731:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.12C>T::	::intergenic_variant:MODIFIER::::	regulatory_region_variant:promoter										-0.0280			0.09,0.94	12.02						0		0	0	0 / 0							PABPC1P10 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)							na	na
chr5	23305156	23305156	C	G	0.0333	1174	0.0000	801	freq-tum;off-target	QUAL=231	CTD-2272G21.2	non_coding_transcript_exon	CTD-2272G21.2:ENST00000511359:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.97G>C::	::intergenic_variant:MODIFIER::::											0.3920			0.27,0.89	3.69						0		0	0	0 / 0														na	na
chr5	112151204	112151204	C	T	0.1014	732	0.0018	541		QUAL=209	APC	stop_gained	APC:ENST00000257430:stop_gained:HIGH:exon9/16:c.847C>T:p.Arg283Ter:,APC:ENST00000457016:stop_gained:HIGH:exon9/16:c.847C>T:p.Arg283Ter:,APC:ENST00000508376:stop_gained:HIGH:exon10/17:c.847C>T:p.Arg283Ter:	APC:NM_000038.5:stop_gained:HIGH:exon9/16:c.847C>T:p.Arg283Ter:,APC:NM_001127510.2:stop_gained:HIGH:exon10/17:c.847C>T:p.Arg283Ter:,APC:NM_001127511.2:stop_gained:HIGH:exon7/14:c.793C>T:p.Arg265Ter:,APC:XM_005271974.1:stop_gained:HIGH:exon9/16:c.847C>T:p.Arg283Ter:,APC:XM_005271975.1:stop_gained:HIGH:exon9/16:c.847C>T:p.Arg283Ter:,APC:XM_005271976.1:stop_gained:HIGH:exon8/15:c.670C>T:p.Arg224Ter:,APC:XM_005271977.1:stop_gained:HIGH:exon9/16:c.847C>T:p.Arg283Ter:		611731 [GENE=APC PHENOS=Adenoma,periampullary,somatic/Desmoid disease,hereditary,135290,Autosomal dominant/Adenomatous polyposis coli,175100,Autosomal dominant/Gardner syndrome,175100,Autosomal dominant/Hepatoblastoma,somatic,114550/Colorectal cancer,somatic,114500/Brain tumor-polyposis syndrome 2,175100,Autosomal dominant/Gastric cancer,somatic,613659];	184999 [pathogenic DISEASE=Hepatocellular carcinoma,Neoplasm of stomach,Hereditary cancer-predisposing syndrome,Malignant Colorectal Neoplasm,Carcinoma of colon,Desmoid disease, hereditary,Familial adenomatous polyposis 1,Familial adenomatous polyposis,not provided];	CM920030 [CLASS=DM MUT=ALT PHEN="Adenomatous polyposis coli" GENE=APC];		rs786201856					5.2150			0.98,0.98	37.00					COSM19679	4	ARO-16,SomaticAndTreatment	0	0	0 / 0			inactivating	[inactivating] aharmes1 13.02.2020			APC (inh=AD oe_syn=1.11 oe_mis=0.99 oe_lof=0.10)	chr5_112151204_C_T	known in: COC-PR	LoF	ENST00000257430	APC	Nonsense	0	1
chr5	138223050	138223050	G	C	0.0635	63	0.0000	44	off-target	QUAL=36	CTNNA1	intron	CTNNA1:ENST00000302763:intron_variant:MODIFIER:intron8/17:c.1144-129G>C::,CTNNA1:ENST00000355078:intron_variant:MODIFIER:intron7/16:c.835-129G>C::,CTNNA1:ENST00000518825:intron_variant:MODIFIER:intron7/17:c.1144-129G>C::,CTNNA1:ENST00000540387:intron_variant:MODIFIER:intron2/11:c.34-129G>C::	CTNNA1:NM_001290307.2:intron_variant:MODIFIER:intron8/18:c.1144-129G>C::,CTNNA1:NM_001290309.2:intron_variant:MODIFIER:intron7/16:c.835-129G>C::,CTNNA1:NM_001290310.2:intron_variant:MODIFIER:intron8/17:c.775-129G>C::,CTNNA1:NM_001290312.1:intron_variant:MODIFIER:intron2/11:c.34-129G>C::,CTNNA1:NM_001323982.1:intron_variant:MODIFIER:intron9/18:c.1144-129G>C::,CTNNA1:NM_001323983.1:intron_variant:MODIFIER:intron8/17:c.1144-129G>C::,CTNNA1:NM_001323984.1:intron_variant:MODIFIER:intron9/18:c.1144-129G>C::,CTNNA1:NM_001323985.1:intron_variant:MODIFIER:intron8/17:c.1144-129G>C::,CTNNA1:NM_001323986.1:intron_variant:MODIFIER:intron8/16:c.1144-129G>C::,CTNNA1:NM_001323987.1:intron_variant:MODIFIER:intron2/11:c.34-129G>C::,CTNNA1:NM_001323988.1:intron_variant:MODIFIER:intron5/14:c.34-129G>C::,CTNNA1:NM_001323989.1:intron_variant:MODIFIER:intron3/12:c.34-129G>C::,CTNNA1:NM_001323990.1:intron_variant:MODIFIER:intron4/13:c.34-129G>C::,CTNNA1:NM_001323991.1:intron_variant:MODIFIER:intron3/12:c.34-129G>C::,CTNNA1:NM_001323992.1:intron_variant:MODIFIER:intron5/14:c.34-129G>C::,CTNNA1:NM_001323993.1:intron_variant:MODIFIER:intron5/14:c.34-129G>C::,CTNNA1:NM_001323994.1:intron_variant:MODIFIER:intron2/11:c.34-129G>C::,CTNNA1:NM_001323995.1:intron_variant:MODIFIER:intron5/14:c.34-129G>C::,CTNNA1:NM_001323996.1:intron_variant:MODIFIER:intron5/14:c.34-129G>C::,CTNNA1:NM_001323997.1:intron_variant:MODIFIER:intron5/14:c.34-129G>C::,CTNNA1:NM_001323998.1:intron_variant:MODIFIER:intron5/14:c.34-129G>C::,CTNNA1:NM_001323999.1:intron_variant:MODIFIER:intron5/14:c.34-129G>C::,CTNNA1:NM_001324000.1:intron_variant:MODIFIER:intron3/12:c.34-129G>C::,CTNNA1:NM_001324001.1:intron_variant:MODIFIER:intron2/10:c.34-129G>C::,CTNNA1:NM_001324002.1:intron_variant:MODIFIER:intron2/12:c.34-129G>C::,CTNNA1:NM_001324003.1:intron_variant:MODIFIER:intron4/14:c.34-129G>C::,CTNNA1:NM_001324004.1:intron_variant:MODIFIER:intron2/12:c.34-129G>C::,CTNNA1:NM_001324005.1:intron_variant:MODIFIER:intron5/15:c.34-129G>C::,CTNNA1:NM_001324006.1:intron_variant:MODIFIER:intron5/15:c.-364-129G>C::,CTNNA1:NM_001324007.1:intron_variant:MODIFIER:intron4/14:c.-364-129G>C::,CTNNA1:NM_001324008.1:intron_variant:MODIFIER:intron2/12:c.-364-129G>C::,CTNNA1:NM_001324009.1:intron_variant:MODIFIER:intron2/12:c.-364-129G>C::,CTNNA1:NM_001324010.1:intron_variant:MODIFIER:intron1/8:c.-61+11764G>C::,CTNNA1:NM_001324011.1:intron_variant:MODIFIER:intron5/13:c.34-129G>C::,CTNNA1:NM_001324012.1:intron_variant:MODIFIER:intron1/9:c.-58+11764G>C::,CTNNA1:NM_001324013.1:intron_variant:MODIFIER:intron2/12:c.-239-129G>C::,CTNNA1:NM_001903.2:intron_variant:MODIFIER:intron8/17:c.1144-129G>C::,CTNNA1:NM_001903.4:intron_variant:MODIFIER:intron8/17:c.1144-129G>C::,CTNNA1:XM_005271897.1:intron_variant:MODIFIER:intron8/16:c.1144-129G>C::,CTNNA1:XM_005271898.1:intron_variant:MODIFIER:intron2/11:c.34-129G>C::,CTNNA1:XM_005271899.1:intron_variant:MODIFIER:intron2/11:c.34-129G>C::		116805 [GENE=CTNNA1 PHENOS=Macular dystrophy,patterned,2,608970,Autosomal dominant];									-0.1770			0.11,0.16	3.71						0		0	0	0 / 0							CTNNA1 (inh=AD oe_syn=0.99 oe_mis=0.55 oe_lof=0.17)	chr5_138223050_G_C	not protein-affecting	.	ENST00000302763	CTNNA1	IntronicSNV	na	na
chr7	142563388	142563388	G	A	0.0381	657	0.0000	415	freq-tum	QUAL=145	EPHB6	splice_region&intron	EPHB6:ENST00000392957:splice_region_variant&intron_variant:LOW:intron8/19:c.1102+3G>A::,EPHB6:ENST00000411471:splice_region_variant&intron_variant:LOW:intron3/14:c.271+3G>A::,EPHB6:ENST00000442129:splice_region_variant&intron_variant:LOW:intron8/19:c.1102+3G>A::	EPHB6:NM_001280794.1:splice_region_variant&intron_variant:LOW:intron7/18:c.226+3G>A::,EPHB6:NM_001280794.2:splice_region_variant&intron_variant:LOW:intron7/18:c.223+3G>A::,EPHB6:NM_001280795.1:splice_region_variant&intron_variant:LOW:intron4/15:c.226+3G>A::,EPHB6:NM_001280795.2:splice_region_variant&intron_variant:LOW:intron4/15:c.223+3G>A::,EPHB6:NM_004445.4:splice_region_variant&intron_variant:LOW:intron5/16:c.1102+3G>A::,EPHB6:NM_004445.5:splice_region_variant&intron_variant:LOW:intron5/16:c.1102+3G>A::,EPHB6:NR_104001.1:splice_region_variant&intron_variant&non_coding_transcript_variant:LOW:intron7/18:n.1130+3G>A::,EPHB6:NR_104001.2:splice_region_variant&intron_variant&non_coding_transcript_variant:LOW:intron7/18:n.1130+3G>A::	regulatory_region_variant:CTCF_binding_site										2.5120			0.34,0.97	16.03		10.10>10.65		0.000/0.004		0		0	0	0 / 0							EPHB6 (inh=n/a oe_syn=1.07 oe_mis=0.89 oe_lof=0.42)	chr7_142563388_G_A	not protein-affecting	.	ENST00000392957	EPHB6	IntronicSNV	na	na
chr8	69030591	69030591	A	-	0.2667	18	0.0000	18	depth-tum;depth-nor;off-target	QUAL=24	PREX2	intron	PREX2:ENST00000288368:intron_variant:MODIFIER:intron26/39:c.3327-180del::	PREX2:NM_024870.2:intron_variant:MODIFIER:intron26/39:c.3327-180del::,PREX2:NM_024870.3:intron_variant:MODIFIER:intron26/39:c.3327-180del::					AluY (SINE/Alu)	rs370448093		0.0197	0,.		1.0150				1.44						1	SomaticAndTreatment	0	8	0 / 0							PREX2 (inh=n/a oe_syn=1.03 oe_mis=0.83 oe_lof=0.47)	chr8_69030590_CA_C	not protein-affecting	ambiguous	ENST00000288368	PREX2	IntronicDeletion	1	0
chr8	110664593	110664593	-	CTT	1.0000	7	0.0000	4	depth-tum;depth-nor;off-target	QUAL=2	SYBU	intron	SYBU:ENST00000408889:intron_variant:MODIFIER:intron1/5:c.-129+28344_-129+28346dup::,SYBU:ENST00000419099:intron_variant:MODIFIER:intron1/7:c.-57-7651_-57-7649dup::,SYBU:ENST00000422135:intron_variant:MODIFIER:intron1/7:c.-57-7651_-57-7649dup::,SYBU:ENST00000532779:intron_variant:MODIFIER:intron1/5:c.26-33328_26-33326dup::,SYBU:ENST00000533171:intron_variant:MODIFIER:intron1/7:c.-57-7651_-57-7649dup::	SYBU:NM_001099743.1:intron_variant:MODIFIER:intron1/7:c.-57-7651_-57-7649dup::,SYBU:NM_001099744.1:intron_variant:MODIFIER:intron1/7:c.-57-7651_-57-7649dup::,SYBU:NM_001099745.1:intron_variant:MODIFIER:intron1/7:c.-57-7651_-57-7649dup::,SYBU:NM_001099746.1:intron_variant:MODIFIER:intron1/5:c.-129+28344_-129+28346dup::	regulatory_region_variant:CTCF_binding_site				(TCC)n (Simple_repeat)	rs34132792	0.3714	0.3133	1774,.						0.52						1	SomaticAndTreatment	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							SYBU (inh=n/a oe_syn=1.05 oe_mis=0.85 oe_lof=0.43)	chr8_110664593_C_CCTT	not protein-affecting	.	ENST00000422135	SYBU	IntronicInsertion	na	na
chr9	92023580	92023580	-	GAG	1.0000	6	0.0000	2	depth-tum;depth-nor;off-target	QUAL=1	SEMA4D	intron	SEMA4D:ENST00000339861:intron_variant:MODIFIER:intron2/18:c.-243-2969_-243-2967dup::,SEMA4D:ENST00000343780:intron_variant:MODIFIER:intron4/20:c.-243-2969_-243-2967dup::,SEMA4D:ENST00000356444:intron_variant:MODIFIER:intron3/16:c.-243-2969_-243-2967dup::,SEMA4D:ENST00000420987:intron_variant:MODIFIER:intron3/19:c.-243-2969_-243-2967dup::,SEMA4D:ENST00000422704:intron_variant:MODIFIER:intron2/15:c.-243-2969_-243-2967dup::,SEMA4D:ENST00000438547:intron_variant:MODIFIER:intron4/17:c.-243-2969_-243-2967dup::,SEMA4D:ENST00000450295:intron_variant:MODIFIER:intron2/15:c.-243-2969_-243-2967dup::,SEMA4D:ENST00000455551:intron_variant:MODIFIER:intron3/19:c.-243-2969_-243-2967dup::	SEMA4D:NM_001142287.1:intron_variant:MODIFIER:intron4/20:c.-243-2969_-243-2967dup::,SEMA4D:NM_006378.3:intron_variant:MODIFIER:intron4/17:c.-243-2969_-243-2967dup::,SEMA4D:XM_005251647.1:intron_variant:MODIFIER:intron5/18:c.-243-2969_-243-2967dup::,SEMA4D:XM_005251648.1:intron_variant:MODIFIER:intron3/16:c.-243-2969_-243-2967dup::,SEMA4D:XM_005251649.1:intron_variant:MODIFIER:intron4/17:c.-243-2969_-243-2967dup::,SEMA4D:XM_005251650.1:intron_variant:MODIFIER:intron3/16:c.-243-2969_-243-2967dup::,SEMA4D:XM_005251651.1:intron_variant:MODIFIER:intron6/19:c.-243-2969_-243-2967dup::,SEMA4D:XM_005251652.1:intron_variant:MODIFIER:intron2/15:c.-243-2969_-243-2967dup::,SEMA4D:XM_005251653.1:intron_variant:MODIFIER:intron4/17:c.-243-2969_-243-2967dup::,SEMA4D:XM_005251654.1:intron_variant:MODIFIER:intron2/15:c.-243-2969_-243-2967dup::,SEMA4D:XM_005251656.1:intron_variant:MODIFIER:intron2/13:c.-243-2969_-243-2967dup::,SEMA4D:XM_005251657.1:intron_variant:MODIFIER:intron2/13:c.-243-2969_-243-2967dup::,SEMA4D:XR_242561.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron3/16:n.449-2969_449-2967dup::,SEMA4D:XR_242562.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron4/17:n.524-2969_524-2967dup::						rs34159561	0.4455	0.3829	2194,.						1.85						0		n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							SEMA4D (inh=n/a oe_syn=0.96 oe_mis=0.88 oe_lof=0.16)	chr9_92023580_A_AGAG	not protein-affecting	.	ENST00000450295	SEMA4D	IntronicInsertion	na	na
chr9	131767814	131767814	T	G	0.2385	130	0.0000	74	off-target	QUAL=116	NUP188	splice_region&intron	NUP188:ENST00000372577:splice_region_variant&intron_variant:LOW:intron40/43:c.4737+5T>G::	NUP188:NM_015354.2:splice_region_variant&intron_variant:LOW:intron40/43:c.4737+5T>G::,:XR_242683.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron1/2:n.32+945A>C::											-0.6330			0.07,0.14	0.02		9.04>10.88		0.000/0.002		13	ALM_Schleimhautmelanom,SomaticAndTreatment	0	38	0 / 8							NUP188 (inh=n/a oe_syn=1.05 oe_mis=0.90 oe_lof=0.20), SH3GLB2 (inh=n/a oe_syn=1.14 oe_mis=0.74 oe_lof=0.41)	chr9_131767814_T_G	not protein-affecting	.	ENST00000372577	NUP188	IntronicSNV	na	na
chr10	61828634	61828634	C	A	0.1739	1959	0.0000	1178		QUAL=791	ANK3	missense,intron	ANK3:ENST00000280772:missense_variant:MODERATE:exon37/44:c.12005G>T:p.Gly4002Val:,ANK3:ENST00000355288:intron_variant:MODIFIER:intron13/20:c.1808-867G>T::,ANK3:ENST00000373827:intron_variant:MODIFIER:intron36/43:c.4388-867G>T::,ANK3:ENST00000503366:intron_variant:MODIFIER:intron36/43:c.4409-867G>T::	ANK3:NM_001149.3:intron_variant:MODIFIER:intron13/20:c.1808-867G>T::,ANK3:NM_001204403.1:intron_variant:MODIFIER:intron36/43:c.4388-867G>T::,ANK3:NM_001204404.1:intron_variant:MODIFIER:intron36/43:c.4409-867G>T::,ANK3:NM_001320874.1:intron_variant:MODIFIER:intron35/42:c.4406-867G>T::,ANK3:NM_020987.3:missense_variant:MODERATE:exon37/44:c.12005G>T:p.Gly4002Val:,ANK3:NM_020987.4:missense_variant:MODERATE:exon37/44:c.12005G>T:p.Gly4002Val:,ANK3:XM_005269710.1:missense_variant:MODERATE:exon37/49:c.12005G>T:p.Gly4002Val:,ANK3:XM_005269711.1:missense_variant:MODERATE:exon37/45:c.12005G>T:p.Gly4002Val:,ANK3:XM_005269712.1:intron_variant:MODIFIER:intron37/46:c.10895-867G>T::,ANK3:XM_005269713.1:intron_variant:MODIFIER:intron37/46:c.10844-867G>T::,ANK3:XM_005269714.1:intron_variant:MODIFIER:intron37/46:c.10817-867G>T::,ANK3:XM_005269715.1:intron_variant:MODIFIER:intron36/43:c.4460-867G>T::,ANK3:XM_005269716.1:intron_variant:MODIFIER:intron35/42:c.4406-867G>T::		600465 [GENE=ANK3 PHENOS=Mental retardation,autosomal recessive,37,615493,Autosomal recessive];									2.9570	D(0.00), , , 	D(0.93), , , 	0.95,0.99	26.90	0.19					0		0	0	0 / 0			unclear	[unclear] aharmes1 13.02.2020			ANK3 (inh=AR oe_syn=1.03 oe_mis=0.84 oe_lof=0.05)	chr10_61828634_C_A	predicted driver: tier 2	Act	ENST00000280772	ANK3	Missense	na	na
chr10	104389735	104389735	C	T	0.1812	309	0.0000	174	off-target	QUAL=174	SUFU	intron	SUFU:ENST00000369902:intron_variant:MODIFIER:intron11/11:c.1366-88C>T::	SUFU:NM_016169.3:intron_variant:MODIFIER:intron11/11:c.1366-88C>T::,SUFU:XM_005269895.1:intron_variant:MODIFIER:intron11/11:c.1369-88C>T::,SUFU:XM_005269896.1:intron_variant:MODIFIER:intron9/9:c.841-88C>T::		607035 [GENE=SUFU PHENOS=Basal cell nevus syndrome,109400,Autosomal dominant/Medulloblastoma,desmoplastic,155255,Autosomal recessive,Autosomal dominant,Somatic mutation/Meningioma,familial,susceptibility to,607174,Autosomal dominant/Joubert syndrome 32,617757,Autosomal recessive];				rs544847008	0.0002				-1.3620			0.02,0.16	0.40						0		0	0	0 / 0							SUFU (inh=AR+AD oe_syn=0.92 oe_mis=0.68 oe_lof=0.00)	chr10_104389735_C_T	not protein-affecting	LoF	ENST00000369902	SUFU	IntronicSNV	0	1
chr11	108199964	108199971	AGGTAACT	-	0.1667	289	0.0000	222		QUAL=156	ATM,C11orf65	splice_donor&coding_sequence&intron,intron	ATM:ENST00000278616:splice_donor_variant&coding_sequence_variant&intron_variant:HIGH:exon49/63intron49/62:c.7307+3_7307+10del::,ATM:ENST00000452508:splice_donor_variant&coding_sequence_variant&intron_variant:HIGH:exon50/64intron50/63:c.7307+3_7307+10del::,C11orf65:ENST00000525729:intron_variant:MODIFIER:intron6/6:c.641-20173_641-20166del::	ATM:NM_000051.3:splice_donor_variant&coding_sequence_variant&intron_variant:HIGH:exon49/63intron49/62:c.7307+3_7307+10del::,C11orf65:NM_001330368.1:intron_variant:MODIFIER:intron6/6:c.641-20173_641-20166del::,C11orf65:XM_005271416.1:intron_variant:MODIFIER:intron6/6:c.641-20173_641-20166del::,ATM:XM_005271561.1:splice_donor_variant&coding_sequence_variant&intron_variant:HIGH:exon49/63intron49/62:c.7307+3_7307+10del::,ATM:XM_005271562.1:splice_donor_variant&coding_sequence_variant&intron_variant:HIGH:exon49/63intron49/62:c.7307+3_7307+10del::,ATM:XM_005271563.1:splice_donor_variant&coding_sequence_variant&intron_variant:HIGH:exon49/63intron49/62:c.7307+3_7307+10del::,ATM:XM_005271564.1:splice_donor_variant&coding_sequence_variant&intron_variant:HIGH:exon43/57intron43/56:c.6263+3_6263+10del::		607585 [GENE=ATM PHENOS=Lymphoma,mantle cell,somatic/Lymphoma,B-cell non-Hodgkin,somatic/Ataxia-telangiectasia,208900,Autosomal recessive/Breast cancer,susceptibility to,114480,Autosomal dominant,Somatic mutation/T-cell prolymphocytic leukemia,somatic];									9.4770										0		0	1	0 / 0			likely_inactivating	[likely_inactivating] aharmes1 13.02.2020			ATM (inh=AR+AD oe_syn=1.05 oe_mis=0.92 oe_lof=0.60), C11ORF65 (inh=n/a oe_syn=0.84 oe_mis=0.92 oe_lof=1.22)	chr11_108199963_CAGGTAACT_C	predicted driver: tier 1	LoF	ENST00000278616	ATM	SpliceDonorDeletion	0,na	1,na
chr12	82878	82880	GCT	-	1.0000	3	0.0000	4	depth-tum;depth-nor;off-target	QUAL=1	ABC7-42389800N19.1	intron&non_coding_transcript	ABC7-42389800N19.1:ENST00000400706:intron_variant&non_coding_transcript_variant:MODIFIER:intron2/10:n.292+3945_292+3947del::	LOC100288778:NR_130745.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron2/10:n.292+3945_292+3947del::	regulatory_region_variant:promoter_flanking_region					rs797038473					-0.1890				3.09						5	eMed-HCC	0	0	0 / 0														na	na
chr12	18715877	18715877	A	C	0.1138	335	0.0000	234	off-target	QUAL=118	PIK3C2G	intron	PIK3C2G:ENST00000266497:intron_variant:MODIFIER:intron25/30:c.3657+51A>C::,PIK3C2G:ENST00000433979:intron_variant:MODIFIER:intron26/31:c.3657+51A>C::,PIK3C2G:ENST00000538779:intron_variant:MODIFIER:intron26/31:c.3780+51A>C::	PIK3C2G:NM_001288772.1:intron_variant:MODIFIER:intron27/32:c.3780+51A>C::,PIK3C2G:NM_001288774.1:intron_variant:MODIFIER:intron27/32:c.3114+51A>C::,PIK3C2G:NM_004570.4:intron_variant:MODIFIER:intron26/31:c.3657+51A>C::,PIK3C2G:NM_004570.5:intron_variant:MODIFIER:intron26/31:c.3657+51A>C::,PIK3C2G:XM_005253393.1:intron_variant:MODIFIER:intron28/33:c.3780+51A>C::											-0.4110			0.02,0.15	2.92						34	ALM_Schleimhautmelanom,Novartis,SomaticAndTreatment	0	1	0 / 0							PIK3C2G (inh=n/a oe_syn=1.01 oe_mis=1.10 oe_lof=0.92)	chr12_18715877_A_C	not protein-affecting	.	ENST00000433979	PIK3C2G	IntronicSNV	na	na
chr12	25398281	25398281	C	T	0.1712	1642	0.0000	1114		QUAL=711	KRAS	missense	KRAS:ENST00000256078:missense_variant:MODERATE:exon2/6:c.38G>A:p.Gly13Asp:PF00071 [Ras family],KRAS:ENST00000311936:missense_variant:MODERATE:exon2/5:c.38G>A:p.Gly13Asp:PF00071 [Ras family],KRAS:ENST00000556131:missense_variant:MODERATE:exon2/3:c.38G>A:p.Gly13Asp:PF00071 [Ras family],KRAS:ENST00000557334:missense_variant:MODERATE:exon2/3:c.38G>A:p.Gly13Asp:PF00071 [Ras family]	KRAS:NM_004985.3:missense_variant:MODERATE:exon2/5:c.38G>A:p.Gly13Asp:,KRAS:NM_004985.4:missense_variant:MODERATE:exon2/5:c.38G>A:p.Gly13Asp:,KRAS:NM_033360.2:missense_variant:MODERATE:exon2/6:c.38G>A:p.Gly13Asp:,KRAS:NM_033360.3:missense_variant:MODERATE:exon2/6:c.38G>A:p.Gly13Asp:,KRAS:XM_005253365.1:missense_variant:MODERATE:exon2/5:c.38G>A:p.Gly13Asp:		190070 [GENE=KRAS PHENOS=Leukemia,acute myeloid,601626,Autosomal dominant,Somatic mutation/Oculoectodermal syndrome,somatic,600268/Breast cancer,somatic,114480/RAS-associated autoimmune leukoproliferative disorder,614470,Autosomal dominant/Cardiofaciocutaneous syndrome 2,615278/Arteriovenous malformation of the brain,somatic,108010/Bladder cancer,somatic,109800/Pancreatic carcinoma,somatic,260350/Lung cancer,somatic,211980/Gastric cancer,somatic,137215/Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200/Noonan syndrome 3,609942,Autosomal dominant];	12580 [pathogenic DISEASE=OCULOECTODERMAL SYNDROME, SOMATIC,Acute myeloid leukemia,Juvenile myelomonocytic leukemia,Non-small cell lung cancer,Neoplasm of the thyroid gland,Neoplasm of the large intestine,Ovarian Neoplasms,Breast adenocarcinoma,RAS-associated autoimmune leukoproliferative disorder];	CM125166 [CLASS=DM? MUT=ALT PHEN="Myelodysplastic/myeloproliferative disease" GENE=KRAS];		rs112445441					7.7460	D(0.04),D(0.04),D(0.04),D(0.03)	B(0.44),B(0.14),B(0.02),D(0.97)	0.98,0.99	24.60	0.83				COSM1140132,COSM1152504,COSM3384257,COSM532,COSM533,COSM534	15	I18D033_ssSC,Leuk,MIPs_Etablierung,Novartis,Ringversuch_EMQN,SomaticAndTreatment	0	0	0 / 0		"[import GPD] Christopher Schroeder 2013-05-24 10:30:43 -type: medical report -drugs: cetuximab, panitumumab, gefitinib KRAS nimmt als GTPase eine zentrale Rolle in der Signaltransduktion ein. Aktivierende Mutationen in KRAS, wie die hier vorliegende Veränderung, korrelieren mit einem schlechten Ansprechen auf anti-EGFR-Antikörper - dieser Effekt wurde für Panitumumab sowie Cetuximab bestätigt.1,2 1. Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of clinical oncology?: official journal of the American Society of Clinical Oncology 26, 1626–34 (2008). 2. Lièvre, A. et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. Journal of clinical oncology?: official journal of the American Society of Clinical Oncology 26, 374–9 (2008)."	activating	[activating] aharmes1 13.02.2020			KRAS (inh=AR+AD oe_syn=0.93 oe_mis=0.34 oe_lof=0.63)	chr12_25398281_C_T	known in: colorectal_cancer;ovarian_cancer;non-small_cell_lung_carcinoma;thyroid_cancer;acute_myeloid_leukemia	Act	ENST00000256078	KRAS	Missense	1	0
chr12	42665574	42665582	TCCCTCCCT	-	1.0000	4	0.0000	5	depth-tum;depth-nor;off-target	QUAL=1	PPHLN1	intron	PPHLN1:ENST00000549190:intron_variant:MODIFIER:intron1/9:c.34+33114_34+33122del::	::intergenic_variant:MODIFIER::::					(CTCC)n (Simple_repeat)	rs112863636		0.1216	233,.		0.2860				2.64						0		n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							PPHLN1 (inh=n/a oe_syn=0.97 oe_mis=0.87 oe_lof=0.56)							na	na
chr13	25033290	25033290	G	C	0.3171	123	0.1475	61	freq-nor;off-target	QUAL=46	PARP4	intron	PARP4:ENST00000381989:intron_variant:MODIFIER:intron19/33:c.2346-30C>G::	PARP4:NM_006437.3:intron_variant:MODIFIER:intron19/33:c.2346-30C>G::						rs4986819	0.0988	0.1323	310,.	0.1836,0.0528,0.0204,0.1140,0.0688	0.2150			0.15,0.17	3.33						1	I17R006	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							PARP4 (inh=n/a oe_syn=1.06 oe_mis=0.99 oe_lof=0.67)	chr13_25033290_G_C	polymorphism	.	ENST00000381989	PARP4	IntronicSNV	na	na
chr13	27250829	27250829	G	A	0.0940	2163	0.0000	1292		QUAL=461	WASF3	synonymous,intron	WASF3:ENST00000335327:synonymous_variant:LOW:exon7/10:c.684G>A:p.Ala228=:,WASF3:ENST00000361042:intron_variant:MODIFIER:intron6/9:c.541-3343G>A::	WASF3:NM_001291965.1:intron_variant:MODIFIER:intron6/9:c.541-3343G>A::,WASF3:NM_006646.5:synonymous_variant:LOW:exon7/10:c.684G>A:p.Ala228=:,WASF3:XM_005266239.1:intron_variant:MODIFIER:intron6/9:c.541-3343G>A::						rs200021774	0.0002	0.0001		0.0000,0.0000,0.0001,0.0001,0.0000	-1.2070			0.06,0.54	9.32						0		0	0	0 / 0							WASF3 (inh=n/a oe_syn=1.03 oe_mis=0.80 oe_lof=0.20)	chr13_27250829_G_A	not protein-affecting	ambiguous	ENST00000335327	WASF3	Synonymous	na	na
chr13	48877777	48877777	G	C	0.0759	145	0.0000	100	off-target	QUAL=83	RB1-DT	non_coding_transcript_exon	RB1-DT:ENST00000433480:non_coding_transcript_exon_variant:MODIFIER:exon1/3:n.21C>G::	LINC00441:NR_046414.1:non_coding_transcript_exon_variant:MODIFIER:exon1/3:n.21C>G::	regulatory_region_variant:promoter										1.1740			0.74,0.49	11.58						0		0	0	0 / 0							RB1-DT (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a), RB1 (inh=AD oe_syn=0.95 oe_mis=0.65 oe_lof=0.05)							na	na
chr14	21882581	21882581	A	C	0.0140	1219	0.0000	724	freq-tum	QUAL=172	CHD8	splice_region&intron	CHD8:ENST00000399982:splice_region_variant&intron_variant:LOW:intron7/36:c.2025-4T>G::,CHD8:ENST00000430710:splice_region_variant&intron_variant:LOW:intron8/37:c.1188-4T>G::,CHD8:ENST00000557364:splice_region_variant&intron_variant:LOW:intron8/37:c.2025-4T>G::	CHD8:NM_001170629.1:splice_region_variant&intron_variant:LOW:intron7/36:c.2025-4T>G::,CHD8:NM_020920.3:splice_region_variant&intron_variant:LOW:intron8/37:c.1188-4T>G::,CHD8:XM_005267923.1:splice_region_variant&intron_variant:LOW:intron8/37:c.2025-4T>G::,CHD8:XM_005267924.1:splice_region_variant&intron_variant:LOW:intron8/37:c.2025-4T>G::,CHD8:XM_005267925.1:splice_region_variant&intron_variant:LOW:intron8/37:c.2025-4T>G::,CHD8:XM_005267926.1:splice_region_variant&intron_variant:LOW:intron8/37:c.2025-4T>G::,CHD8:XM_005267927.1:splice_region_variant&intron_variant:LOW:intron8/36:c.2025-4T>G::,CHD8:XM_005267928.1:splice_region_variant&intron_variant:LOW:intron5/34:c.354-4T>G::		610528 [GENE=CHD8 PHENOS=Autism,susceptibility to,18,615032,Autosomal dominant];									1.8760			0.31,0.42	8.02		7.10>8.24		0.000/0.054		0		0	0	0 / 0							CHD8 (inh=AD oe_syn=0.94 oe_mis=0.56 oe_lof=0.04)	chr14_21882581_A_C	not protein-affecting	LoF	ENST00000399982	CHD8	IntronicSNV	na	na
chr15	57212017	57212017	A	C	0.0782	550	0.0000	291	off-target	QUAL=78	TCF12	intron	TCF12:ENST00000267811:intron_variant:MODIFIER:intron1/19:c.-22-73A>C::,TCF12:ENST00000333725:intron_variant:MODIFIER:intron1/20:c.-22-73A>C::,TCF12:ENST00000438423:intron_variant:MODIFIER:intron1/20:c.-12-83A>C::,TCF12:ENST00000452095:intron_variant:MODIFIER:intron1/20:c.-22-73A>C::,TCF12:ENST00000557843:intron_variant:MODIFIER:intron1/19:c.-12-83A>C::	TCF12:NM_001322151.1:intron_variant:MODIFIER:intron1/20:c.-22-73A>C::,TCF12:NM_001322152.1:intron_variant:MODIFIER:intron1/20:c.-22-73A>C::,TCF12:NM_001322154.1:intron_variant:MODIFIER:intron1/20:c.-674-73A>C::,TCF12:NM_001322156.1:intron_variant:MODIFIER:intron1/21:c.-258-73A>C::,TCF12:NM_001322157.1:intron_variant:MODIFIER:intron1/19:c.-22-73A>C::,TCF12:NM_001322158.1:intron_variant:MODIFIER:intron1/20:c.-258-73A>C::,TCF12:NM_001322159.1:intron_variant:MODIFIER:intron1/20:c.-22-73A>C::,TCF12:NM_001322161.1:intron_variant:MODIFIER:intron1/20:c.-22-73A>C::,TCF12:NM_001322162.1:intron_variant:MODIFIER:intron1/20:c.-22-73A>C::,TCF12:NM_001322164.1:5_prime_UTR_variant:MODIFIER:exon1/20:c.-95A>C::,TCF12:NM_001322165.1:5_prime_UTR_variant:MODIFIER:exon1/19:c.-95A>C::,TCF12:NM_003205.3:intron_variant:MODIFIER:intron1/19:c.-22-73A>C::,TCF12:NM_207036.1:intron_variant:MODIFIER:intron1/20:c.-12-83A>C::,TCF12:NM_207037.1:intron_variant:MODIFIER:intron1/20:c.-22-73A>C::,TCF12:NM_207038.1:intron_variant:MODIFIER:intron1/19:c.-12-83A>C::,TCF12:XM_005254613.1:intron_variant:MODIFIER:intron1/21:c.-258-73A>C::	regulatory_region_variant:promoter,TF_binding_site_variant	600480 [GENE=TCF12 PHENOS=Craniosynostosis 3,615314,Autosomal dominant];									-3.1880			0.00,0.13	2.08						4	SomaticAndTreatment	0	0	0 / 0							ZNF280D (inh=n/a oe_syn=1.13 oe_mis=0.85 oe_lof=0.26), TCF12 (inh=AD oe_syn=1.15 oe_mis=0.87 oe_lof=0.21)	chr15_57212017_A_C	not protein-affecting	Act	ENST00000438423	TCF12	IntronicSNV	0	0
chr15	88558875	88558875	C	T	0.1599	2526	0.0000	1486		QUAL=915	NTRK3	intron	NTRK3:ENST00000317501:intron_variant:MODIFIER:intron13/14:c.1585+17213G>A::,NTRK3:ENST00000355254:intron_variant:MODIFIER:intron13/17:c.1585+17213G>A::,NTRK3:ENST00000357724:intron_variant:MODIFIER:intron12/17:c.1561+17213G>A::,NTRK3:ENST00000360948:intron_variant:MODIFIER:intron13/18:c.1585+17213G>A::,NTRK3:ENST00000394480:intron_variant:MODIFIER:intron14/18:c.1585+17213G>A::,NTRK3:ENST00000540489:intron_variant:MODIFIER:intron12/13:c.1585+17213G>A::,NTRK3:ENST00000542733:intron_variant:MODIFIER:intron12/15:c.1291+17213G>A::,NTRK3:ENST00000557856:intron_variant:MODIFIER:intron11/15:c.1561+17213G>A::,NTRK3:ENST00000558676:intron_variant:MODIFIER:intron11/13:c.1561+17213G>A::	NTRK3:NM_001007156.2:intron_variant:MODIFIER:intron14/15:c.1585+17213G>A::,NTRK3:NM_001012338.2:intron_variant:MODIFIER:intron14/19:c.1585+17213G>A::,NTRK3:NM_001243101.1:intron_variant:MODIFIER:intron13/17:c.1561+17213G>A::,NTRK3:NM_001320134.1:intron_variant:MODIFIER:intron12/12:c.1585+17213G>A::,NTRK3:NM_001320135.1:intron_variant:MODIFIER:intron12/15:c.1291+17213G>A::,NTRK3:NM_002530.3:intron_variant:MODIFIER:intron14/18:c.1585+17213G>A::,NTRK3:XM_005254928.1:intron_variant:MODIFIER:intron12/17:c.1585+17213G>A::,NTRK3:XM_005254929.1:intron_variant:MODIFIER:intron13/17:c.1585+17213G>A::,NTRK3:XM_005254930.1:intron_variant:MODIFIER:intron12/15:c.1291+17213G>A::	regulatory_region_variant:enhancer,regulatory_region_variant:CTCF_binding_site				L2d2 (LINE/L2)						-1.0010			0.00,0.06	0.04						0		0	0	0 / 0							NTRK3 (inh=AD oe_syn=1.20 oe_mis=0.77 oe_lof=0.12)	chr15_88558875_C_T	not protein-affecting	Act	ENST00000360948	NTRK3	IntronicSNV	1	0
chr15	88576889	88576889	G	A	0.1052	972	0.0000	620		QUAL=289	NTRK3	intron	NTRK3:ENST00000317501:intron_variant:MODIFIER:intron12/14:c.1397-613C>T::,NTRK3:ENST00000355254:intron_variant:MODIFIER:intron12/17:c.1397-613C>T::,NTRK3:ENST00000357724:intron_variant:MODIFIER:intron11/17:c.1373-613C>T::,NTRK3:ENST00000360948:intron_variant:MODIFIER:intron12/18:c.1397-613C>T::,NTRK3:ENST00000394480:intron_variant:MODIFIER:intron13/18:c.1397-613C>T::,NTRK3:ENST00000540489:intron_variant:MODIFIER:intron11/13:c.1397-613C>T::,NTRK3:ENST00000542733:intron_variant:MODIFIER:intron11/15:c.1103-613C>T::,NTRK3:ENST00000557856:intron_variant:MODIFIER:intron10/15:c.1373-613C>T::,NTRK3:ENST00000558676:intron_variant:MODIFIER:intron10/13:c.1373-613C>T::	NTRK3:NM_001007156.2:intron_variant:MODIFIER:intron13/15:c.1397-613C>T::,NTRK3:NM_001012338.2:intron_variant:MODIFIER:intron13/19:c.1397-613C>T::,NTRK3:NM_001243101.1:intron_variant:MODIFIER:intron12/17:c.1373-613C>T::,NTRK3:NM_001320134.1:intron_variant:MODIFIER:intron11/12:c.1397-613C>T::,NTRK3:NM_001320135.1:intron_variant:MODIFIER:intron11/15:c.1103-613C>T::,NTRK3:NM_002530.3:intron_variant:MODIFIER:intron13/18:c.1397-613C>T::,NTRK3:XM_005254928.1:intron_variant:MODIFIER:intron11/17:c.1397-613C>T::,NTRK3:XM_005254929.1:intron_variant:MODIFIER:intron12/17:c.1397-613C>T::,NTRK3:XM_005254930.1:intron_variant:MODIFIER:intron11/15:c.1103-613C>T::											-0.1030			0.01,0.11	0.59						0		0	0	0 / 0							NTRK3 (inh=AD oe_syn=1.20 oe_mis=0.77 oe_lof=0.12)	chr15_88576889_G_A	not protein-affecting	Act	ENST00000360948	NTRK3	IntronicSNV	1	0
chr15	90631838	90631838	C	G	0.1737	3754	0.0000	2249		QUAL=1454	IDH2	missense,intron	IDH2:ENST00000330062:missense_variant:MODERATE:exon4/11:c.515G>C:p.Arg172Thr:PF00180 [Isocitrate/isopropylmalate dehydrogenase],IDH2:ENST00000539790:missense_variant:MODERATE:exon2/9:c.125G>C:p.Arg42Thr:PF00180 [Isocitrate/isopropylmalate dehydrogenase],IDH2:ENST00000540499:missense_variant:MODERATE:exon4/11:c.359G>C:p.Arg120Thr:PF00180 [Isocitrate/isopropylmalate dehydrogenase],IDH2:ENST00000559482:intron_variant:MODIFIER:intron2/7:c.208-104G>C::	IDH2:NM_001289910.1:missense_variant:MODERATE:exon4/11:c.359G>C:p.Arg120Thr:,IDH2:NM_001290114.1:missense_variant:MODERATE:exon2/9:c.125G>C:p.Arg42Thr:,IDH2:NM_002168.2:missense_variant:MODERATE:exon4/11:c.515G>C:p.Arg172Thr:,IDH2:NM_002168.3:missense_variant:MODERATE:exon4/11:c.515G>C:p.Arg172Thr:,IDH2:XM_005254893.1:missense_variant:MODERATE:exon4/11:c.359G>C:p.Arg120Thr:,IDH2:XM_005254894.1:missense_variant:MODERATE:exon2/9:c.125G>C:p.Arg42Thr:		147650 [GENE=IDH2 PHENOS=D-2-hydroxyglutaric aciduria 2,613657];									7.8000	D(0.00),D(0.00),D(0.00), 	D(1.00),D(1.00),D(1.00), 	1.00,0.99	22.80	0.75				COSM1636997,COSM33732,COSM33733	0		0	0	0 / 0			likely_activating	PMID: 19228619 [likely_activating] aharmes1 13.02.2020			IDH2 (inh=AD oe_syn=1.27 oe_mis=0.76 oe_lof=0.15)	chr15_90631838_C_G	predicted driver: tier 1	Act	ENST00000330062	IDH2	Missense	1	0
chr15	93515799	93515799	G	A	0.1277	47	0.0000	31	off-target	QUAL=69	CHD2	intron	CHD2:ENST00000394196:intron_variant:MODIFIER:intron19/38:c.2505+152G>A::,CHD2:ENST00000557381:intron_variant:MODIFIER:intron19/37:c.2505+152G>A::	CHD2:NM_001271.3:intron_variant:MODIFIER:intron19/38:c.2505+152G>A::,CHD2:XM_005254834.1:intron_variant:MODIFIER:intron18/37:c.2544+152G>A::,CHD2:XM_005254835.1:intron_variant:MODIFIER:intron17/36:c.2499+152G>A::,CHD2:XM_005254836.1:intron_variant:MODIFIER:intron18/37:c.2211+152G>A::,CHD2:XM_005254837.1:intron_variant:MODIFIER:intron16/35:c.2130+152G>A::,CHD2:XM_005254838.1:intron_variant:MODIFIER:intron18/28:c.2544+152G>A::,CHD2:XR_243201.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron18/32:n.2974+152G>A::		602119 [GENE=CHD2 PHENOS=Epileptic encephalopathy,childhood-onset,615369,Autosomal dominant];				rs111441731					-0.2370			0.00,0.05	1.69						8	SomaticAndTreatment,TEST_SomaticAndTreatment	56	28	0 / 0							CHD2 (inh=AD oe_syn=0.95 oe_mis=0.53 oe_lof=0.03)	chr15_93515799_G_A	not protein-affecting	LoF	ENST00000394196	CHD2	IntronicSNV	0	1
chr16	46389424	46389424	A	C	0.4286	7	0.0000	11	depth-tum;depth-nor;off-target	QUAL=19		intergenic	::intergenic_variant:MODIFIER::::	::intergenic_variant:MODIFIER::::						rs4477740								0.00,0.04	8.97						0		0	0	0 / 0														na	na
chr17	29661652	29661652	T	C	0.1472	360	0.0000	187	off-target	QUAL=157	NF1	intron	NF1:ENST00000356175:intron_variant:MODIFIER:intron38/56:c.5750-204T>C::,NF1:ENST00000358273:intron_variant:MODIFIER:intron39/57:c.5813-204T>C::	NF1:NM_000267.3:intron_variant:MODIFIER:intron38/56:c.5750-204T>C::,NF1:NM_001042492.2:intron_variant:MODIFIER:intron39/57:c.5813-204T>C::,NF1:XM_005257983.1:intron_variant:MODIFIER:intron39/58:c.5813-204T>C::,NF1:XM_005257984.1:intron_variant:MODIFIER:intron38/57:c.5750-204T>C::,NF1:XM_005257985.1:intron_variant:MODIFIER:intron39/58:c.5813-204T>C::,NF1:XM_005257986.1:intron_variant:MODIFIER:intron39/58:c.5813-204T>C::		613113 [GENE=NF1 PHENOS=Neurofibromatosis-Noonan syndrome,601321,Autosomal dominant/Leukemia,juvenile myelomonocytic,607785,Autosomal dominant,Somatic mutation/Neurofibromatosis,familial spinal,162210,Autosomal dominant/Watson syndrome,193520,Autosomal dominant/Neurofibromatosis,type 1,162200,Autosomal dominant];				rs112966582		0.0001		0.0000,0.0000,0.0000,0.0000,0.0000	1.0990			0.31,0.95	16.86						0		0	0	0 / 0							NF1 (inh=AD oe_syn=0.94 oe_mis=0.52 oe_lof=0.22)	chr17_29661652_T_C	not protein-affecting	LoF	ENST00000358273	NF1	IntronicSNV	0	1
chr19	18856767	18856767	G	T	0.0916	963	0.0000	558		QUAL=237	CRTC1	synonymous	CRTC1:ENST00000321949:synonymous_variant:LOW:exon3/14:c.378G>T:p.Arg126=:,CRTC1:ENST00000338797:synonymous_variant:LOW:exon4/15:c.426G>T:p.Arg142=:,CRTC1:ENST00000594658:synonymous_variant:LOW:exon3/14:c.255G>T:p.Arg85=:,CRTC1:ENST00000601916:synonymous_variant:LOW:exon2/10:c.153G>T:p.Arg51=:	CRTC1:NM_001098482.1:synonymous_variant:LOW:exon4/15:c.426G>T:p.Arg142=:,CRTC1:NM_015321.2:synonymous_variant:LOW:exon3/14:c.378G>T:p.Arg126=:,CRTC1:XM_005259833.1:synonymous_variant:LOW:exon4/14:c.426G>T:p.Arg142=:,CRTC1:XM_005259834.1:synonymous_variant:LOW:exon3/13:c.378G>T:p.Arg126=:,CRTC1:XM_005259835.1:synonymous_variant:LOW:exon4/15:c.426G>T:p.Arg142=:,CRTC1:XM_005259836.1:synonymous_variant:LOW:exon4/14:c.426G>T:p.Arg142=:		607536 [GENE=CRTC1 PHENOS=Mucoepidermoid salivary gland carcinoma];				rs774288381					-0.3580			0.22,0.97	11.43						0		0	0	0 / 0							CRTC1 (inh=n/a oe_syn=1.05 oe_mis=0.67 oe_lof=0.21)	chr19_18856767_G_T	not protein-affecting	Act	ENST00000338797	CRTC1	Synonymous	1	0
chr19	36228710	36228710	G	A	0.0492	1608	0.0000	867	freq-tum;off-target	QUAL=246	KMT2B	intron,intron&non_coding_transcript	KMT2B:ENST00000222270:intron_variant:MODIFIER:intron34/36:c.7659-50G>A::,KMT2B:ENST00000420124:intron_variant:MODIFIER:intron34/36:c.7659-50G>A::,KMT2B:ENST00000607650:intron_variant&non_coding_transcript_variant:MODIFIER:intron34/36:n.7659-50G>A::	KMT2B:NM_014727.1:intron_variant:MODIFIER:intron34/36:c.7659-50G>A::,KMT2B:NM_014727.2:intron_variant:MODIFIER:intron34/36:c.7659-50G>A::,KMT2B:XM_005259446.1:intron_variant:MODIFIER:intron32/34:c.5382-50G>A::	regulatory_region_variant:CTCF_binding_site	606834 [GENE=KMT2B PHENOS=Dystonia 28,childhood-onset,617284,Autosomal dominant];									-0.3280			0.08,0.24	1.96						0		0	0	0 / 0							KMT2B (inh=AD oe_syn=1.22 oe_mis=0.76 oe_lof=0.03), IGFLR1 (inh=n/a oe_syn=1.16 oe_mis=1.16 oe_lof=0.77), U2AF1L4 (inh=n/a oe_syn=0.90 oe_mis=1.08 oe_lof=0.97)	chr19_36228710_G_A	not protein-affecting	.	ENST00000222270	WBP7	IntronicSNV	na	na
chr20	30385135	30385135	A	G	0.1260	389	0.0000	258	off-target	QUAL=173	TPX2	intron	TPX2:ENST00000300403:intron_variant:MODIFIER:intron15/17:c.1834-72A>G::,TPX2:ENST00000340513:intron_variant:MODIFIER:intron16/18:c.1942-72A>G::	TPX2:NM_012112.4:intron_variant:MODIFIER:intron15/17:c.1834-72A>G::,TPX2:XM_005260339.1:intron_variant:MODIFIER:intron16/18:c.1942-72A>G::,TPX2:XM_005260340.1:intron_variant:MODIFIER:intron15/17:c.1834-72A>G::											-0.0920			0.06,0.14	4.82						0		0	0	0 / 0							TPX2 (inh=n/a oe_syn=0.97 oe_mis=0.93 oe_lof=0.09)	chr20_30385135_A_G	not protein-affecting	.	ENST00000300403	TPX2	IntronicSNV	na	na
chrX	20159910	20159910	G	A	0.3375	80	0.0612	49	freq-nor;off-target	QUAL=79	EIF1AX	5'UTR	EIF1AX:ENST00000379593:5_prime_UTR_variant:MODIFIER:exon1/6:c.-152C>T::,EIF1AX:ENST00000379607:5_prime_UTR_variant:MODIFIER:exon1/7:c.-152C>T::	EIF1AX:NM_001412.3:5_prime_UTR_variant:MODIFIER:exon1/7:c.-152C>T::	regulatory_region_variant:promoter					rs187747791		0.0000	0,0		0.1980			0.10,0.48	10.21						18	ALM_Schleimhautmelanom,Novartis,SomaticAndTreatment	0	39	0 / 0							EIF1AX (inh=n/a oe_syn=0.86 oe_mis=0.08 oe_lof=0.00), EIF1AX-AS1 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)	chrX_20159910_G_A	not protein-affecting	LoF	ENST00000379607	EIF1AX	5-UTRSNV	0	0
chrX	110406672	110406672	T	-	0.1667	27	0.0000	17	depth-nor;off-target	QUAL=33	PAK3	intron	PAK3:ENST00000262836:intron_variant:MODIFIER:intron6/14:c.646-108del::,PAK3:ENST00000360648:intron_variant:MODIFIER:intron7/15:c.709-108del::,PAK3:ENST00000372007:intron_variant:MODIFIER:intron9/17:c.601-108del::,PAK3:ENST00000372010:intron_variant:MODIFIER:intron10/18:c.646-108del::,PAK3:ENST00000417227:intron_variant:MODIFIER:intron6/14:c.664-108del::,PAK3:ENST00000425146:intron_variant:MODIFIER:intron6/14:c.601-108del::,PAK3:ENST00000446737:intron_variant:MODIFIER:intron7/15:c.601-108del::,PAK3:ENST00000518291:intron_variant:MODIFIER:intron10/18:c.709-108del::,PAK3:ENST00000519681:intron_variant:MODIFIER:intron10/18:c.664-108del::	PAK3:NM_001128166.1:intron_variant:MODIFIER:intron7/15:c.601-108del::,PAK3:NM_001128166.2:intron_variant:MODIFIER:intron7/15:c.601-108del::,PAK3:NM_001128167.1:intron_variant:MODIFIER:intron6/14:c.601-108del::,PAK3:NM_001128167.2:intron_variant:MODIFIER:intron6/14:c.601-108del::,PAK3:NM_001128168.1:intron_variant:MODIFIER:intron7/15:c.709-108del::,PAK3:NM_001128168.2:intron_variant:MODIFIER:intron11/19:c.709-108del::,PAK3:NM_001128172.1:intron_variant:MODIFIER:intron6/14:c.664-108del::,PAK3:NM_001128172.2:intron_variant:MODIFIER:intron6/14:c.664-108del::,PAK3:NM_001128173.1:intron_variant:MODIFIER:intron6/14:c.646-108del::,PAK3:NM_001128173.2:intron_variant:MODIFIER:intron10/18:c.646-108del::,PAK3:NM_001324325.1:intron_variant:MODIFIER:intron7/15:c.601-108del::,PAK3:NM_001324326.1:intron_variant:MODIFIER:intron7/15:c.601-108del::,PAK3:NM_001324327.1:intron_variant:MODIFIER:intron9/17:c.646-108del::,PAK3:NM_001324328.1:intron_variant:MODIFIER:intron8/16:c.646-108del::,PAK3:NM_001324329.1:intron_variant:MODIFIER:intron10/18:c.646-108del::,PAK3:NM_001324330.1:intron_variant:MODIFIER:intron7/15:c.601-108del::,PAK3:NM_001324331.1:intron_variant:MODIFIER:intron8/16:c.601-108del::,PAK3:NM_001324332.1:intron_variant:MODIFIER:intron9/17:c.601-108del::,PAK3:NM_001324333.1:intron_variant:MODIFIER:intron9/17:c.646-108del::,PAK3:NM_001324334.1:intron_variant:MODIFIER:intron8/16:c.601-108del::,PAK3:NM_002578.3:intron_variant:MODIFIER:intron9/17:c.601-108del::,PAK3:NM_002578.4:intron_variant:MODIFIER:intron9/17:c.601-108del::,PAK3:NR_136747.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/17:n.1079-108del::,PAK3:NR_136748.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron6/15:n.776-108del::,PAK3:XM_005262131.1:intron_variant:MODIFIER:intron11/19:c.709-108del::,PAK3:XM_005262132.1:intron_variant:MODIFIER:intron10/18:c.646-108del::,PAK3:XM_005262133.1:intron_variant:MODIFIER:intron9/17:c.601-108del::,PAK3:XM_005262134.1:intron_variant:MODIFIER:intron8/16:c.595-108del::,PAK3:XM_005262135.1:intron_variant:MODIFIER:intron9/17:c.598-108del::,PAK3:XR_244474.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron10/19:n.1267-108del::		300142 [GENE=PAK3 PHENOS=Mental retardation,X-linked 30/47,300558,X-linked recessive];				rs1295467485		0.0011	0,0		1.6280				1.41						4	ARO-16,SomaticAndTreatment	0	0	0 / 0							PAK3 (inh=XLR oe_syn=0.95 oe_mis=0.32 oe_lof=0.09)	chrX_110406671_CT_C	not protein-affecting	.	ENST00000360648	PAK3	IntronicDeletion	na	na
chrX	119345517	119345517	G	A	0.0532	94	0.0000	54	off-target	QUAL=65	EEF1A1P30	non_coding_transcript_exon	EEF1A1P30:ENST00000429708:non_coding_transcript_exon_variant:MODIFIER:exon2/4:n.695C>T::	::intergenic_variant:MODIFIER::::											2.3420			0.56,0.93	8.46						0		0	0	0 / 0							EEF1A1P30 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)							na	na
chrX	147026333	147026333	C	T	0.0821	140	0.0119	89	off-target	QUAL=48	FMR1	intron	FMR1:ENST00000218200:intron_variant:MODIFIER:intron13/15:c.1409-56C>T::,FMR1:ENST00000370470:intron_variant:MODIFIER:intron14/16:c.1472-131C>T::,FMR1:ENST00000370471:intron_variant:MODIFIER:intron13/15:c.1276-131C>T::,FMR1:ENST00000370475:intron_variant:MODIFIER:intron14/16:c.1472-56C>T::,FMR1:ENST00000370477:intron_variant:MODIFIER:intron13/15:c.1409-92C>T::,FMR1:ENST00000439526:intron_variant:MODIFIER:intron13/15:c.1403-56C>T::,FMR1:ENST00000440235:intron_variant:MODIFIER:intron8/10:c.413-56C>T::	FMR1:NM_001185075.1:intron_variant:MODIFIER:intron13/15:c.1276-131C>T::,FMR1:NM_001185076.1:intron_variant:MODIFIER:intron13/15:c.1409-56C>T::,FMR1:NM_001185081.1:intron_variant:MODIFIER:intron12/14:c.1213-131C>T::,FMR1:NM_001185082.1:intron_variant:MODIFIER:intron13/15:c.1409-131C>T::,FMR1:NM_002024.5:intron_variant:MODIFIER:intron14/16:c.1472-56C>T::,FMR1:NR_033699.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron13/15:n.1505-56C>T::,FMR1:NR_033700.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron12/14:n.1442-56C>T::,FMR1:XM_005262323.1:intron_variant:MODIFIER:intron14/16:c.1472-92C>T::,FMR1:XM_005262324.1:intron_variant:MODIFIER:intron14/16:c.1472-56C>T::,FMR1:XM_005262325.1:intron_variant:MODIFIER:intron14/16:c.1472-131C>T::,FMR1:XM_005262326.1:intron_variant:MODIFIER:intron13/15:c.1409-56C>T::,FMR1:XM_005262327.1:intron_variant:MODIFIER:intron13/15:c.1403-56C>T::,FMR1:XM_005262328.1:intron_variant:MODIFIER:intron14/16:c.1472-131C>T::,FMR1:XM_005262329.1:intron_variant:MODIFIER:intron14/16:c.1472-56C>T::,FMR1:XM_005262330.1:intron_variant:MODIFIER:intron13/15:c.1409-140C>T::,FMR1:XM_005262331.1:3_prime_UTR_variant:MODIFIER:exon15/15:c.*698C>T::		309550 [GENE=FMR1 PHENOS=Premature ovarian failure 1,311360,X-linked/Fragile X tremor/ataxia syndrome,300623,X-linked dominant/Fragile X syndrome,300624,X-linked dominant];				rs201348821					1.4030			0.00,0.86	16.41						1	eMed-HCC	0	36	0 / 0							FMR1 (inh=XLD oe_syn=0.80 oe_mis=0.47 oe_lof=0.20), FMR1-IT1 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)	chrX_147026333_C_T	not protein-affecting	LoF	ENST00000370475	FMR1	IntronicSNV	na	na
chrY	2722625	2722625	C	G	0.2941	103	0.0000	69	off-target	QUAL=131	RPS4Y1	intron	RPS4Y1:ENST00000250784:intron_variant:MODIFIER:intron4/6:c.361-16C>G::	RPS4Y1:NM_001008.3:intron_variant:MODIFIER:intron4/6:c.361-16C>G::,RPS4Y1:XM_005262568.1:intron_variant:MODIFIER:intron4/6:c.388-16C>G::											0.0020			0.00,0.07	2.70		6.63>4.85				0		0	0	0 / 0							RPS4Y1 (inh=n/a oe_syn=1.28 oe_mis=0.54 oe_lof=0.00)	chrY_2722625_C_G	not protein-affecting	.	ENST00000250784	RPS4Y1	IntronicSNV	na	na
chrY	58827271	58827271	A	G	0.2727	11	0.0000	13	depth-tum;depth-nor;off-target	QUAL=29		intergenic	::intergenic_variant:MODIFIER::::	::intergenic_variant:MODIFIER::::	regulatory_region_variant:CTCF_binding_site					rs143218002					0.6910			0.06,-99.00	9.22						3	HepaVac,Novartis,eMed-HCC	0	2	0 / 0														na	na
